RGNX Reports $12.3M Q4 Rev, $0.08 EPS, Advances RGX-202 Phase I/II Data, $100M AbbVie Milestone, $500M Potential Deal, 2026 Catalysts
REGENXBIO Inc. · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.14
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS